The stock of Insys Therapeutics Inc (NASDAQ:INSY) is a huge mover today! About 385,077 shares traded hands. Insys Therapeutics Inc (NASDAQ:INSY) has declined 23.69% since March 9, 2016 and is downtrending. It has underperformed by 31.10% the S&P500.
The move comes after 8 months negative chart setup for the $819.67 million company. It was reported on Oct, 12 by Barchart.com. We have $10.93 PT which if reached, will make NASDAQ:INSY worth $65.57 million less.
Analysts await Insys Therapeutics Inc (NASDAQ:INSY) to report earnings on November, 3. INSY’s profit will be $4.14 million for 49.50 P/E if the $0.06 EPS becomes a reality. After $0.06 actual EPS reported by Insys Therapeutics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Insys Therapeutics Inc (NASDAQ:INSY) Ratings Coverage
Out of 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Insys Therapeutics has been the topic of 9 analyst reports since August 4, 2015 according to StockzIntelligence Inc. Jefferies maintained the shares of INSY in a report on Wednesday, February 24 with “Buy” rating. The firm has “Buy” rating given on Tuesday, April 12 by Jefferies. The stock has “Hold” rating given by Oppenheimer on Tuesday, August 4. Jefferies maintained Insys Therapeutics Inc (NASDAQ:INSY) on Thursday, August 4 with “Buy” rating. RBC Capital Markets maintained Insys Therapeutics Inc (NASDAQ:INSY) rating on Thursday, September 22. RBC Capital Markets has “Outperform” rating and $26 price target. The firm has “Buy” rating given on Thursday, April 14 by Janney Capital. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The stock of Insys Therapeutics Inc (NASDAQ:INSY) has “Buy” rating given on Monday, October 10 by Jefferies. As per Friday, August 14, the company rating was downgraded by Zacks.
According to Zacks Investment Research, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.”
Insitutional Activity: The institutional sentiment decreased to 0.7 in Q2 2016. Its down 0.36, from 1.06 in 2016Q1. The ratio dropped, as 22 funds sold all Insys Therapeutics Inc shares owned while 42 reduced positions. 13 funds bought stakes while 32 increased positions. They now own 31.30 million shares or 9.76% less from 34.69 million shares in 2016Q1.
Pictet Asset Mngmt Ltd holds 0.01% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 87,426 shares. Creative Planning has 0% invested in the company for 1,508 shares. The Texas-based Next Incorporated has invested 0% in Insys Therapeutics Inc (NASDAQ:INSY). Rock Springs Cap Management Ltd Partnership holds 0.35% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 365,500 shares. Smithfield Co holds 0% or 188 shares in its portfolio. Legal General Public, a United Kingdom-based fund reported 6,247 shares. Morgan Stanley, a New York-based fund reported 120,736 shares. Tower Capital Limited Company (Trc) last reported 0% of its portfolio in the stock. Adage Capital Prtnrs Grp Inc Limited Liability Com last reported 0.01% of its portfolio in the stock. California Employees Retirement, a California-based fund reported 88,600 shares. Deutsche Fincl Bank Ag has invested 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY). Ladenburg Thalmann Financial Ser holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 2,435 shares. The New York-based Van Eck Corp has invested 0% in Insys Therapeutics Inc (NASDAQ:INSY). State Street Corp has 1.05 million shares for 0% of their US portfolio. Clinton Gp reported 17,368 shares or 0.01% of all its holdings.
Insider Transactions: Since May 11, 2016, the stock had 2 buys, and 4 sales for $170,592 net activity. The insider JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989 bought $105,853. FOURTEAU PATRICK sold 15,000 shares worth $276,900. BRENNAN DANIEL sold $110,752 worth of stock. Shares for $270,300 were sold by STANLEY THEODORE H on Tuesday, August 16.
More news for Insys Therapeutics Inc (NASDAQ:INSY) were recently published by: Businessinsider.com, which released: “A pharmaceutical company is fighting marijuana legalization because it would …” on September 13, 2016. Globenewswire.com‘s article titled: “Insys Therapeutics Announces CEO Succession Plan” and published on September 21, 2016 is yet another important article.
INSY Company Profile
Insys Therapeutics, Inc., incorporated on June 15, 1990, is a commercial-stage specialty pharmaceutical company. The Firm develops and commercializes supportive care products. Subsys is the Company’s marketed product. Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and is a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Firm markets Subsys through its field sales force focused on supportive care physicians in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.